SCHEMBL900115

SCHEMBL900115

FC(F)Oc1c[c]c(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.37
ALDH1A1 P00352 5/20 0.36
LMNA P02545 4/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
HTT P42858 3/20 0.36
ATM Q13315 2/20 0.36
ALOX15 P16050 2/20 0.36
HSP90AA1 P07900 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
CCR6 P51684 1/20 0.36
GFER P55789 1/20 0.36
ADAM17 P78536 1/20 0.36
MAPT P10636 4/20 0.34
NPSR1 Q6W5P4 3/20 0.34
RAB9A P51151 3/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321358 0.78 ALDH1A3 (0.41) ALDH1A1LMNAKMT2AMEN1HPGD
SCHEMBL1069126 0.76 ALOX15 (0.41) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL900706 0.76 DRD1 (0.38) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL900696 0.76 DRD1 (0.38) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL1067320 0.74 DRD1 (0.37) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL1067603 0.74 DRD1 (0.41) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL11066303 0.74 DRD1 (0.39) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL8267 0.73
SCHEMBL11065049 0.72 DRD1 (0.56) DRD1ALDH1A1LMNAKMT2AMEN1
SCHEMBL158565 0.72 GPR3 (0.37) ALDH1A1KMT2AMEN1CCR6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
CN-107690434-B Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity UCB生物制药私人有限公司 2021-07-30 CN disclosed
EP-3303337-B1 FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2020-05-27 EP disclosed
US-10472362-B2 Fused tricyclic imidazo pyrazines as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2019-11-12 US disclosed
EP-3080114-B1 FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-10-02 EP disclosed
EP-3080113-B1 FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-09-18 EP disclosed
EP-3080121-B1 FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-09-04 EP disclosed
CN-105814049-B Fused tricyclic imdazole derivatives as TNF active regulator UCB生物制药私人有限公司 2019-03-12 CN disclosed
WO-2011069894-A1 TRIAZOLE COMPOUNDS, USE THEREOF, AND AGENTS CONTAINING SAME BASF SE (DE) 2011-06-16 WO disclosed
WO-2011069916-A1 TRIAZOLE COMPOUNDS, USE THEREOF AS A FUNGICIDE, AND AGENTS COMPRISING SAME BASF SE (DE) 2011-06-16 WO disclosed
WO-2011006886-A2 AZOLE COMPOUNDS CARRYING A SULFUR SUBSTITUENT XIV BASF SE (DE) 2011-01-20 WO disclosed
WO-2010149758-A1 ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES BASF SE (DE) 2010-12-29 WO disclosed
US-20100317515-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same BASF SE (DE) 2010-12-16 US disclosed
US-20100311581-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same BASF SE (DE) 2010-12-09 US disclosed
CN-101902914-A Azolylmethyloxiranes, use thereof and compositions comprising same BASF SE 2010-12-01 CN disclosed
US-20100273651-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same BASF SE (DE) 2010-10-28 US disclosed
EP-2235005-A2 AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME BASF SE (DE) 2010-10-06 EP disclosed
WO-2009077500-A2 AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME BASF SE (DE) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317515-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same XDH, NOX5, TET1 DRD1 1560/4885ALDH1A1 20/4885LMNA 4209/4885
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC DRD1 4619/4885ALDH1A1 1221/4885LMNA 2007/4885
US-10472362-B2 Fused tricyclic imidazo pyrazines as modulators of TNF activity TNF, TNFRSF1A, TNFRSF9 DRD1 3161/4885ALDH1A1 1283/4885LMNA 3187/4885
US-20100273651-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same XDH, SQOR, NOX5 DRD1 1470/4885ALDH1A1 14/4885LMNA 4264/4885
US-20100311581-A1 Azolylmethyloxiranes, use Thereof and Agents Containing the Same XDH, DAO, DHODH DRD1 739/4885ALDH1A1 25/4885LMNA 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.